BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28081538)

  • 1. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.
    Kazarian A; Blyuss O; Metodieva G; Gentry-Maharaj A; Ryan A; Kiseleva EM; Prytomanova OM; Jacobs IJ; Widschwendter M; Menon U; Timms JF
    Br J Cancer; 2017 Feb; 116(4):501-508. PubMed ID: 28081538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
    Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
    PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.
    Burford B; Gentry-Maharaj A; Graham R; Allen D; Pedersen JW; Nudelman AS; Blixt O; Fourkala EO; Bueti D; Dawnay A; Ford J; Desai R; David L; Trinder P; Acres B; Schwientek T; Gammerman A; Reis CA; Silva L; Osório H; Hallett R; Wandall HH; Mandel U; Hollingsworth MA; Jacobs I; Fentiman I; Clausen H; Taylor-Papadimitriou J; Menon U; Burchell JM
    Br J Cancer; 2013 May; 108(10):2045-55. PubMed ID: 23652307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel serum metabolome score for breast cancer diagnosis.
    Rashed R; Darwish H; Omran M; Belal A; Zahran F
    Br J Biomed Sci; 2020 Oct; 77(4):196-201. PubMed ID: 32546046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol.
    Giordano L; Gallo F; Petracci E; Chiorino G; Segnan N;
    BMC Cancer; 2017 Nov; 17(1):785. PubMed ID: 29166878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of blood markers for early breast cancer diagnosis.
    Bayo J; Castaño MA; Rivera F; Navarro F
    Clin Transl Oncol; 2018 Apr; 20(4):467-475. PubMed ID: 28808872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS).
    Fourkala EO; Blyuss O; Field H; Gunu R; Ryan A; Barth J; Jacobs I; Zaikin A; Dawnay A; Menon U
    Steroids; 2016 Jun; 110():62-69. PubMed ID: 27091764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and validation of breast cancer early detection biomarkers in preclinical samples.
    Li CI
    Horm Cancer; 2011 Apr; 2(2):125-31. PubMed ID: 21761335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.
    Buas MF; Rho JH; Chai X; Zhang Y; Lampe PD; Li CI
    Breast Cancer Res Treat; 2015 Sep; 153(2):445-54. PubMed ID: 26319120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.
    Hao W; Zhang X; Xiu B; Yang X; Hu S; Liu Z; Duan C; Jin S; Ying X; Zhao Y; Han X; Hao X; Fan Y; Johnson H; Meng D; Persson JL; Zhang H; Feng X; Huang Y
    Tumour Biol; 2016 Jul; 37(7):8909-16. PubMed ID: 26753956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
    Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.
    Swellam M; Ramadan A; El-Hussieny EA; Bakr NM; Hassan NM; Sobeih ME; EzzElArab LR
    J Cell Biochem; 2019 Aug; 120(8):12321-12330. PubMed ID: 30825229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer.
    Ali HQ; Mahdi NK; Al-Jowher MH
    J Pak Med Assoc; 2013 Sep; 63(9):1138-41. PubMed ID: 24601193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
    Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
    Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Serum Integrin αvβ3 & Vitronectin in the Early Diagnosis of Breast Cancer.
    Radwan AF; Ismael OE; Fawzy A; El-Mesallamy HO
    Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk.
    Nichols HB; Baird DD; Stanczyk FZ; Steiner AZ; Troester MA; Whitworth KW; Sandler DP
    Cancer Prev Res (Phila); 2015 Jun; 8(6):528-34. PubMed ID: 25873369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection.
    Garczyk S; von Stillfried S; Antonopoulos W; Hartmann A; Schrauder MG; Fasching PA; Anzeneder T; Tannapfel A; Ergönenc Y; Knüchel R; Rose M; Dahl E
    PLoS One; 2015; 10(4):e0122106. PubMed ID: 25875093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and identification of serum protein peak at 6648 m/z as a novel indicator in breast cancer based on mass spectrometry.
    Song D; Yue L; Zhan Y; Zhang J; Yan Z; Fan Y; Yang H; Zhang D; Liu Q; Xia Z; Qin P; Jia J; Yue M; Yu J; Zheng S; Yang F; Wang J
    Discov Med; 2017 May; 23(128):283-294. PubMed ID: 28715644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.